Regression of Multiple Meningiomas after Discontinuation of Chronic Hormone Therapy: A Case Report

Abstract

Introduction Meningiomas are more common in females and frequently express progesterone and estrogen receptors. Recent studies have revealed a high incidence of meningiomas in situations in which estrogen/progesterone levels are increased such as pregnancy, gender reassignment therapy, and fertility treatment. While the relationship remains unclear and controversial, these findings suggest exposure to high levels of endogenous or exogenous hormones may increase the risk of developing a meningioma.

Patients and Methods A 40-year-old female with a history of endometriosis treated with chronic progesterone therapy presented with a visual deficit and was found to have multiple meningiomas, which regressed after cessation of exogenous progesterone.

Conclusion A history of chronic hormone therapy should be included when evaluating patients diagnosed with meningiomas, particularly at a younger age and with multiple meningiomas. Cessation of exogenous progesterone resulting in regression of meningiomas suggests a direct action of progesterone on growth. Future studies are warranted to better elucidate this relationship.

Keywords

meningioma - estrogen - progesterone - endometriosis

• References

• 1 Commins DL, Atkinson RD, Burnett ME. Review of meningioma histopathology. Neurosurg Focus 2007; 23 (04) E3
• 2 Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010; 99 (03) 307-314
• 3 Chacko JG, Miller JL, Angtuaco EJ. Spontaneous postpartum resolution of vision loss caused by a progesterone receptor-positive tuberculum sellae meningioma. J Neuroophthalmol 2010; 30 (02) 132-134
• 4 Chakravarthy V, Kaplan B, Gospodarev V, Myers H, De Los Reyes K, Achiriloaie A. Houdini tumor: case report and literature review of pregnancy-associated meningioma. World Neurosurg 2018; 114: e1261-e1265
• 5 Lusis EA, Scheithauer BW, Yachnis AT. et al. Meningiomas in pregnancy: a clinicopathologic study of 17 cases. Neurosurgery 2012; 71 (05) 951-961
• 6 Claus EB, Black PM, Bondy ML. et al. Exogenous hormone use and meningioma risk: what do we tell our patients?. Cancer 2007; 110 (03) 471-476
• 7 Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg 2013; 118 (03) 649-656
• 8 Deipolyi AR, Han SJ, Parsa AT. Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy. J Clin Neurosci 2010; 17 (10) 1324-1326
• 9 Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med 2007; 357 (23) 2411-2412
• 10 Harland TA, Freeman JL, Davern M. et al. Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. J Neurooncol 2017; 0 (00) 1-7
• 11 Practice T, Medicine R. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014; 101 (04) 927-935
• 12 Ron IG, Soyfer V, Goldray D, Inbar MJ, Weisman Y. A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy. Eur J Cancer 2002; 38 (11) 1490-1494
• 13 Koech F, Orege J, Ndiangui F, Macharia B, Mbaruku N. Multiple intracranial meningiomas: a review of the literature and a case report. Case Rep Surg 2013; 2013: 131962
• 14 Sheehy JP, Crockard HA. Multiple meningiomas: a long-term review. J Neurosurg 1983; 59 (01) 1-5
• 15 Wong RH, Wong AK, Vick N, Farhat HI. Natural history of multiple meningiomas. Surg Neurol Int 2013; 4 (01) 71
• 16 Claus EB, Calvocoressi L, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M. Family and personal medical history and risk of meningioma. J Neurosurg 2011; 115 (06) 1072-1077
• 17 Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 1994; 80 (03) 527-534
• 18 Olson JJ, Beck DW, Schlechte J, Loh PM. Hormonal manipulation of meningiomas in vitro. J Neurosurg 1986; 65 (01) 99-107
• 19 Grunberg SM, Weiss MH, Spitz IM. et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991; 74 (06) 861-866
• 20 Ji Y, Rankin C, Grunberg S. et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG s9005. J Clin Oncol 2015; 33 (34) 4093-4098
• 21 Knight EJ, McDonald MJ. Recurrence and progression of meningioma in male-to-female transgender individuals during exogenous hormone use. Int J Transgenderism 2013; 14 (01) 18-23
• 22 Vadivelu S, Sharer L, Schulder M. Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg 2010; 112 (05) 920-924
• 23 Peyre M, Gaillard S, de Marcellus C. et al. Progestin-associated shift of meningioma mutational landscape. Ann Oncol 2017; (February): 1-6
• 24 Shahin MN, Magill ST, Dalle Ore CL. et al. Fertility treatment is associated with multiple meningiomas and younger age at diagnosis. J Neurooncol 2019; 143 (01) 137-144
• 25 Raj R, Korja M, Koroknay-Pál P, Niemelä M. Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: a report of two cases and a brief literature review. Surg Neurol Int 2018; 9 (01) 109
• 26 Ter Wengel PV, Martin E, Gooren L, Den Heijer M, Peerdeman SM. Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature. Andrologia 2016; 48 (10) 1130-1137